CL2022001476A1 - Use of reboxetine to treat disorders of the nervous system - Google Patents
Use of reboxetine to treat disorders of the nervous systemInfo
- Publication number
- CL2022001476A1 CL2022001476A1 CL2022001476A CL2022001476A CL2022001476A1 CL 2022001476 A1 CL2022001476 A1 CL 2022001476A1 CL 2022001476 A CL2022001476 A CL 2022001476A CL 2022001476 A CL2022001476 A CL 2022001476A CL 2022001476 A1 CL2022001476 A1 CL 2022001476A1
- Authority
- CL
- Chile
- Prior art keywords
- reboxetine
- nervous system
- treat disorders
- esreboxetine
- cataplexy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
Abstract
En el presente documento se describen los métodos para el tratamiento de la narcolepsia con cataplexia, los cuales comprenden la administración de la reboxetina (la que incluye la esreboxetina) a un ser humano que lo necesite. La reboxetina (la que incluye la esreboxetina) también se puede utilizar en la elaboración de un medicamento para el tratamiento de la narcolepsia con cataplexia. También se dan a conocer en este documento los kits que comprenden una composición farmacéutica que comprende la reboxetina (la que incluye la esreboxetina) y las instrucciones para usar la composición farmacéutica para el tratamiento de la narcolepsia con cataplexia en un ser humano.Described herein are methods for the treatment of narcolepsy with cataplexy, which comprise administering reboxetine (including esreboxetine) to a human in need thereof. Reboxetine (including esreboxetine) may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (which includes esreboxetine) and instructions for using the pharmaceutical composition for the treatment of cataplexy narcolepsy in a human.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962943077P | 2019-12-03 | 2019-12-03 | |
US201962946295P | 2019-12-10 | 2019-12-10 | |
US16/740,329 US20200147093A1 (en) | 2018-10-15 | 2020-01-10 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
US16/740,409 US11351175B2 (en) | 2018-10-15 | 2020-01-11 | Use of reboxetine to treat narcolepsy |
US16/740,410 US20200147095A1 (en) | 2018-10-15 | 2020-01-11 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
US16/740,411 US20200147096A1 (en) | 2018-10-15 | 2020-01-11 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022001476A1 true CL2022001476A1 (en) | 2023-04-10 |
Family
ID=76221823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022001476A CL2022001476A1 (en) | 2019-12-03 | 2022-06-03 | Use of reboxetine to treat disorders of the nervous system |
Country Status (4)
Country | Link |
---|---|
CL (1) | CL2022001476A1 (en) |
EC (1) | ECSP22048726A (en) |
TW (2) | TW202313055A (en) |
WO (1) | WO2021113163A1 (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60022916T2 (en) * | 1999-07-01 | 2006-07-06 | Pharmacia & Upjohn Co. Llc, Kalamazoo | Reboxetine for the treatment of peripheral neuropathies |
EP1763354A2 (en) * | 2004-06-09 | 2007-03-21 | Pfizer Limited | Use of reboxetine for the treatment of pain |
PT2968208T (en) * | 2013-03-13 | 2022-10-28 | Aerial Biopharma Llc | Treatment of cataplexy |
EP3866768A4 (en) * | 2018-10-15 | 2022-01-05 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
-
2020
- 2020-11-30 WO PCT/US2020/062560 patent/WO2021113163A1/en active Application Filing
- 2020-12-02 TW TW111147054A patent/TW202313055A/en unknown
- 2020-12-02 TW TW109142504A patent/TWI790510B/en active
-
2022
- 2022-06-03 CL CL2022001476A patent/CL2022001476A1/en unknown
- 2022-06-17 EC ECSENADI202248726A patent/ECSP22048726A/en unknown
Also Published As
Publication number | Publication date |
---|---|
TWI790510B (en) | 2023-01-21 |
ECSP22048726A (en) | 2022-07-29 |
TW202128179A (en) | 2021-08-01 |
TW202313055A (en) | 2023-04-01 |
WO2021113163A1 (en) | 2021-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022001743A1 (en) | Gamma-Hydroxybutyrate (GHB) Dosage | |
MX2020004467A (en) | Methods for treating or preventing asthma by administering an il-4r antagonist. | |
ECSP22023220A (en) | MONO OR DISUBSTITUTED INDOL DERIVATIVES AS INHIBITORS OF DENGUE VIRAL REPLICATION | |
CL2023001949A1 (en) | Antibodies targeting HIV gp120 and methods of use (divisional patent application no. 3422-2020) | |
GT201700246A (en) | METHODS AND KITS TO TREAT DEPRESSION | |
CL2021000924A1 (en) | Use of reboxetine for the treatment of narcolepsy | |
CO2019000938A2 (en) | Nmda spiro-lactam modulators and methods of use thereof | |
AR107871A1 (en) | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS | |
CO2019000944A2 (en) | Modulators of the nmda spiro-lactam and bis-spiro-lactam receptor and use thereof | |
CO2021015793A2 (en) | Methods of treating or preventing asthma by administering an il-33 antagonist | |
CL2019000247A1 (en) | Modulators of the nmda spiro-lactam receptor and use thereof. | |
CL2019002218A1 (en) | Triple combination formulations and methods to treat or reduce the risk of cardiovascular disease. | |
BR112017006113A8 (en) | Auristatin uses, pharmaceutical compositions, dosage forms for cancer treatment and kits. | |
CO2023001953A2 (en) | Phospholipid compounds and their uses | |
CL2021002646A1 (en) | Methods and compositions for use in the treatment of cancer without psychoactive effects | |
CO2022007814A2 (en) | Tyk2 pseudokinase ligands | |
CO2023013050A2 (en) | Psilocybin compositions, methods of preparing them and methods of using them | |
BR112022007721A2 (en) | METHOD FOR THE TREATMENT OF DEMENTIA | |
CO2022014499A2 (en) | nlrp3 modulators | |
CO2020007601A2 (en) | Modified brucella vaccine strain for the treatment of brucellosis | |
CL2020000508A1 (en) | Anti-egfr drug-antibody (adc) conjugates and their uses. | |
CL2020000270A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor. | |
MX2020004513A (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same. | |
BR112019004540A2 (en) | method for treating dementia in a patient, pharmaceutical composition, method for treating dementia in a patient, method for reducing the likelihood of developing dementia in a patient, composition for use in treating dementia in a patient, composition and composition for use in reducing dementia likelihood of developing dementia in a patient undergoing long therapy with a non-steroidal anti-inflammatory drug or aspirin | |
CR20220250A (en) | METHODS FOR THE TREATMENT OF DEPRESSIVE DISORDERS |